Bearishness Around Pfizer Gilead Sparks Opportunity
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
Controlling spending in your 20s comes down to consistent routines: track, limit impulse buys, and automate saving to reinforce discipline.
21,066 articlesWall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
Hyperliquid's native token continues a sharp weekly decline, reviving bearish bets as traders weigh on-chain signals ...
A top Nomura strategist says equities are priced for chaos, but the odds of a sweeping market crash remain low as dat...
Goldman Sachs has quietly built a $154 million stake in spot XRP ETFs, making it the largest disclosed holder as XRP ...
The YieldMax PYPL Option Income Strategy ETF is under pressure as its strategy to harvest option premiums collides wi...
Four pure-play quantum stocks slid 6%–9% in a coordinated downturn, signaling a sector-wide rotation amid broader mar...
Oil prices decline as optimism over a potential Iran conflict settlement grows, lifting expectations for fuel-heavy i...
Investors who bought the Global X Lithium & Battery Tech ETF last June are seeing a 125% return as lithium demand imp...
Taiwan Semiconductor Manufacturing Co. is trading at a valuation many investors describe as dirt cheap as AI-driven d...
NovaCore Technologies enters the second half of 2026 with a multi-year backlog, AI revenue momentum, and cloud growth...
XRP’s leverage washout has cooled, but the next move hinges on real buying. ETFs and spot demand must prove durable t...
Investors chasing income may be chasing sky-high yields that hide fragile payouts. Three BDCs illustrate growing payo...